Developer of therapies to treat the causes of autoimmune disease, including type 1 diabetes and other autoimmune diseases. The company's technology is based on the identification of specific protein processing and signaling defects in the autoreactive lymphocytes that cause autoimmune disease. The identification of these defects has yielded a approach to the treatment of autoimmunity based on selective destruction of lymphocytes responsible for autoimmune reactions. [Keywords: lupus, scleroderma]
Keel Pharmaceuticals Headquarter Location
215 First Street Suite 104
Cambridge, Massachusetts, 02142,
Predict your next investment
The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.
Expert Collections containing Keel Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Keel Pharmaceuticals is included in 1 Expert Collection, including Diabetes.